David Moreno
Concepts (308)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Waldenstrom Macroglobulinemia | 7 | 2025 | 19 | 3.850 |
Why?
| | Multiple Myeloma | 14 | 2026 | 282 | 3.170 |
Why?
| | Monoclonal Gammopathy of Undetermined Significance | 4 | 2025 | 11 | 2.690 |
Why?
| | Lymphoma, B-Cell | 3 | 2023 | 130 | 2.110 |
Why?
| | Saccharomyces cerevisiae | 13 | 2025 | 556 | 2.060 |
Why?
| | Saccharomyces cerevisiae Proteins | 11 | 2025 | 403 | 2.000 |
Why?
| | Myeloid Differentiation Factor 88 | 5 | 2025 | 105 | 1.570 |
Why?
| | Cellular Senescence | 3 | 2024 | 205 | 1.270 |
Why?
| | Proteostasis | 2 | 2020 | 28 | 1.270 |
Why?
| | Immunoglobulin M | 5 | 2025 | 287 | 1.240 |
Why?
| | Molecular Chaperones | 3 | 2019 | 198 | 1.180 |
Why?
| | Immunotherapy, Adoptive | 7 | 2026 | 356 | 1.180 |
Why?
| | B-Cell Maturation Antigen | 5 | 2025 | 13 | 1.150 |
Why?
| | Plasmacytoma | 2 | 2022 | 19 | 0.940 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2025 | 21 | 0.910 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2025 | 60 | 0.900 |
Why?
| | Translocation, Genetic | 1 | 2025 | 109 | 0.870 |
Why?
| | Chromosome Aberrations | 1 | 2025 | 160 | 0.850 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2022 | 33 | 0.740 |
Why?
| | Calcaneus | 1 | 2022 | 30 | 0.740 |
Why?
| | Pharmaceutical Preparations | 2 | 2020 | 178 | 0.720 |
Why?
| | Galactokinase | 1 | 2020 | 4 | 0.680 |
Why?
| | Sarcoma, Ewing | 1 | 2022 | 100 | 0.680 |
Why?
| | Epistasis, Genetic | 1 | 2020 | 68 | 0.660 |
Why?
| | Automation | 1 | 2020 | 100 | 0.650 |
Why?
| | Cell Enlargement | 2 | 2019 | 8 | 0.650 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2025 | 668 | 0.640 |
Why?
| | High-Throughput Screening Assays | 2 | 2020 | 157 | 0.630 |
Why?
| | Leishmania infantum | 4 | 2014 | 8 | 0.620 |
Why?
| | Graft vs Host Disease | 2 | 2019 | 254 | 0.620 |
Why?
| | DNA Replication | 2 | 2023 | 240 | 0.620 |
Why?
| | Bone Neoplasms | 1 | 2022 | 253 | 0.620 |
Why?
| | G1 Phase Cell Cycle Checkpoints | 1 | 2019 | 10 | 0.610 |
Why?
| | Cell Size | 1 | 2019 | 89 | 0.600 |
Why?
| | Cell Cycle Checkpoints | 1 | 2019 | 97 | 0.600 |
Why?
| | Histone Deacetylases | 1 | 2020 | 209 | 0.600 |
Why?
| | Time-Lapse Imaging | 1 | 2019 | 22 | 0.590 |
Why?
| | Intravital Microscopy | 1 | 2019 | 24 | 0.590 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2025 | 1787 | 0.590 |
Why?
| | Heat-Shock Response | 1 | 2019 | 77 | 0.570 |
Why?
| | Chromatin | 2 | 2025 | 529 | 0.550 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2019 | 772 | 0.430 |
Why?
| | Receptors, Immunologic | 2 | 2025 | 215 | 0.410 |
Why?
| | Carbamates | 2 | 2010 | 46 | 0.410 |
Why?
| | Mutation | 5 | 2025 | 4013 | 0.390 |
Why?
| | Cyclins | 4 | 2021 | 92 | 0.380 |
Why?
| | Smoldering Multiple Myeloma | 2 | 2021 | 7 | 0.360 |
Why?
| | Receptors, CXCR4 | 2 | 2022 | 88 | 0.340 |
Why?
| | Imides | 1 | 2010 | 11 | 0.340 |
Why?
| | Antiprotozoal Agents | 1 | 2010 | 16 | 0.340 |
Why?
| | T-Lymphocytes | 3 | 2025 | 2002 | 0.330 |
Why?
| | Selenium | 1 | 2010 | 49 | 0.330 |
Why?
| | CDC28 Protein Kinase, S cerevisiae | 2 | 2021 | 7 | 0.330 |
Why?
| | Humans | 42 | 2026 | 141187 | 0.310 |
Why?
| | Prognosis | 3 | 2025 | 4073 | 0.310 |
Why?
| | Dexamethasone | 2 | 2025 | 380 | 0.300 |
Why?
| | Genomics | 2 | 2025 | 814 | 0.300 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2024 | 830 | 0.290 |
Why?
| | HSP40 Heat-Shock Proteins | 2 | 2019 | 27 | 0.280 |
Why?
| | Small Molecule Libraries | 2 | 2020 | 98 | 0.260 |
Why?
| | Skin Neoplasms | 2 | 2023 | 849 | 0.250 |
Why?
| | Gene Expression Regulation, Fungal | 3 | 2023 | 71 | 0.250 |
Why?
| | Protein Biosynthesis | 4 | 2022 | 444 | 0.240 |
Why?
| | Signaling Lymphocytic Activation Molecule Family | 1 | 2025 | 7 | 0.240 |
Why?
| | Neurotoxicity Syndromes | 1 | 2026 | 38 | 0.240 |
Why?
| | Cytokinesis | 1 | 2025 | 50 | 0.230 |
Why?
| | Aged | 11 | 2026 | 24574 | 0.230 |
Why?
| | Positive Regulatory Domain I-Binding Factor 1 | 1 | 2025 | 17 | 0.230 |
Why?
| | Sulfonamides | 2 | 2024 | 520 | 0.230 |
Why?
| | Bortezomib | 1 | 2025 | 53 | 0.230 |
Why?
| | Hyperpigmentation | 1 | 2005 | 27 | 0.230 |
Why?
| | Thalidomide | 1 | 2025 | 44 | 0.220 |
Why?
| | Antineoplastic Agents | 3 | 2024 | 2166 | 0.220 |
Why?
| | Histone Acetyltransferases | 1 | 2025 | 62 | 0.220 |
Why?
| | Remote Consultation | 1 | 2005 | 59 | 0.220 |
Why?
| | Protein Kinase Inhibitors | 2 | 2024 | 914 | 0.210 |
Why?
| | DNA Helicases | 1 | 2025 | 140 | 0.210 |
Why?
| | Neoplasm, Residual | 1 | 2025 | 132 | 0.210 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2025 | 109 | 0.210 |
Why?
| | Receptors, Virus | 1 | 2024 | 96 | 0.210 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2025 | 147 | 0.210 |
Why?
| | Bone Marrow | 2 | 2024 | 302 | 0.210 |
Why?
| | Aged, 80 and over | 6 | 2025 | 7856 | 0.210 |
Why?
| | Cell Cycle | 3 | 2023 | 597 | 0.210 |
Why?
| | Hematologic Neoplasms | 1 | 2026 | 159 | 0.210 |
Why?
| | Middle Aged | 12 | 2026 | 34434 | 0.210 |
Why?
| | Male | 19 | 2026 | 69783 | 0.200 |
Why?
| | Disease-Free Survival | 2 | 2022 | 715 | 0.200 |
Why?
| | Quinazolines | 1 | 2024 | 250 | 0.190 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2024 | 222 | 0.190 |
Why?
| | Immunoglobulin Light-chain Amyloidosis | 1 | 2021 | 8 | 0.180 |
Why?
| | Cell Cycle Proteins | 2 | 2023 | 624 | 0.180 |
Why?
| | Models, Molecular | 5 | 2020 | 1603 | 0.180 |
Why?
| | Molecular Dynamics Simulation | 2 | 2020 | 246 | 0.180 |
Why?
| | Peptide Elongation Factor 1 | 1 | 2021 | 9 | 0.180 |
Why?
| | Drug Discovery | 2 | 2020 | 147 | 0.180 |
Why?
| | Signal Transduction | 3 | 2025 | 5144 | 0.180 |
Why?
| | Skin Diseases | 2 | 2018 | 147 | 0.180 |
Why?
| | Immunoglobulin Light Chains | 1 | 2021 | 51 | 0.180 |
Why?
| | Allografts | 1 | 2022 | 147 | 0.180 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2021 | 85 | 0.180 |
Why?
| | Female | 19 | 2026 | 75515 | 0.170 |
Why?
| | Patient Selection | 1 | 2005 | 688 | 0.170 |
Why?
| | Endodeoxyribonucleases | 2 | 2014 | 73 | 0.170 |
Why?
| | Genes, Regulator | 1 | 2020 | 36 | 0.170 |
Why?
| | Dendritic Spines | 1 | 2021 | 68 | 0.170 |
Why?
| | Polymerase Chain Reaction | 2 | 2022 | 1056 | 0.170 |
Why?
| | Cytoplasmic Granules | 1 | 2021 | 93 | 0.160 |
Why?
| | Hydroxamic Acids | 1 | 2020 | 92 | 0.160 |
Why?
| | Calibration | 1 | 2020 | 152 | 0.160 |
Why?
| | Cell Line, Tumor | 5 | 2025 | 3469 | 0.160 |
Why?
| | Niacinamide | 1 | 2020 | 82 | 0.160 |
Why?
| | Feedback, Physiological | 1 | 2020 | 81 | 0.160 |
Why?
| | Models, Biological | 3 | 2024 | 1828 | 0.160 |
Why?
| | Epigenomics | 1 | 2020 | 114 | 0.160 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2025 | 898 | 0.160 |
Why?
| | Melanoma | 2 | 2024 | 772 | 0.160 |
Why?
| | Photopheresis | 1 | 2019 | 9 | 0.150 |
Why?
| | RNA, Messenger | 2 | 2025 | 2828 | 0.150 |
Why?
| | S Phase Cell Cycle Checkpoints | 1 | 2019 | 4 | 0.150 |
Why?
| | Sepsis | 1 | 2026 | 616 | 0.150 |
Why?
| | Cell Nucleolus | 1 | 2019 | 17 | 0.150 |
Why?
| | Treatment Outcome | 5 | 2025 | 11120 | 0.150 |
Why?
| | Diagnosis, Differential | 2 | 2026 | 1498 | 0.150 |
Why?
| | Luminescent Agents | 1 | 2019 | 8 | 0.150 |
Why?
| | Actins | 1 | 2021 | 423 | 0.150 |
Why?
| | Spatio-Temporal Analysis | 1 | 2019 | 34 | 0.150 |
Why?
| | Acute Disease | 2 | 2019 | 1008 | 0.150 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2022 | 393 | 0.150 |
Why?
| | Cyclin G1 | 1 | 2018 | 1 | 0.150 |
Why?
| | Cell Growth Processes | 1 | 2018 | 53 | 0.140 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 1073 | 0.140 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2019 | 74 | 0.140 |
Why?
| | Lymphoma | 1 | 2020 | 228 | 0.140 |
Why?
| | Transcription, Genetic | 1 | 2025 | 1487 | 0.140 |
Why?
| | Spectrometry, Fluorescence | 1 | 2019 | 167 | 0.140 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 313 | 0.140 |
Why?
| | Centromere | 1 | 2018 | 59 | 0.140 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2019 | 131 | 0.140 |
Why?
| | Adenosine Triphosphatases | 1 | 2019 | 159 | 0.140 |
Why?
| | Luminescent Proteins | 1 | 2019 | 181 | 0.140 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2019 | 186 | 0.140 |
Why?
| | Stress, Physiological | 1 | 2021 | 454 | 0.130 |
Why?
| | Biomarkers | 2 | 2026 | 4174 | 0.130 |
Why?
| | Macrophages | 1 | 2024 | 1561 | 0.130 |
Why?
| | Pleural Effusion | 1 | 2017 | 60 | 0.120 |
Why?
| | Biological Evolution | 1 | 2020 | 490 | 0.120 |
Why?
| | Adult | 9 | 2026 | 39177 | 0.120 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 660 | 0.120 |
Why?
| | Chronic Disease | 2 | 2019 | 1816 | 0.120 |
Why?
| | Disease Management | 3 | 2025 | 633 | 0.120 |
Why?
| | Recombinant Proteins | 1 | 2019 | 1357 | 0.120 |
Why?
| | Mitochondria | 2 | 2014 | 967 | 0.110 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1448 | 0.110 |
Why?
| | Endoplasmic Reticulum | 1 | 2017 | 265 | 0.110 |
Why?
| | DNA-Binding Proteins | 1 | 2022 | 1478 | 0.110 |
Why?
| | Molecular Conformation | 3 | 2020 | 147 | 0.110 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2015 | 150 | 0.110 |
Why?
| | Exonucleases | 1 | 2014 | 8 | 0.110 |
Why?
| | Mice | 7 | 2025 | 18048 | 0.110 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2015 | 183 | 0.110 |
Why?
| | HIV Infections | 3 | 2019 | 3017 | 0.110 |
Why?
| | Endonucleases | 1 | 2014 | 32 | 0.110 |
Why?
| | NADH, NADPH Oxidoreductases | 1 | 2013 | 26 | 0.100 |
Why?
| | Pyridones | 1 | 2015 | 176 | 0.100 |
Why?
| | Glucocorticoids | 1 | 2017 | 533 | 0.100 |
Why?
| | Disease Models, Animal | 4 | 2025 | 4404 | 0.100 |
Why?
| | Apoptosis | 2 | 2014 | 2574 | 0.090 |
Why?
| | Immunoglobulin A | 2 | 2025 | 214 | 0.090 |
Why?
| | HeLa Cells | 2 | 2025 | 640 | 0.090 |
Why?
| | Incidence | 1 | 2018 | 2794 | 0.090 |
Why?
| | Consensus | 2 | 2025 | 704 | 0.090 |
Why?
| | Parasitic Sensitivity Tests | 1 | 2010 | 3 | 0.090 |
Why?
| | Inhibitory Concentration 50 | 1 | 2010 | 91 | 0.080 |
Why?
| | Anti-HIV Agents | 2 | 2010 | 859 | 0.080 |
Why?
| | Transplantation, Autologous | 2 | 2022 | 280 | 0.080 |
Why?
| | HIV | 2 | 2010 | 250 | 0.080 |
Why?
| | Animals | 8 | 2025 | 37657 | 0.080 |
Why?
| | History, 21st Century | 2 | 2021 | 220 | 0.080 |
Why?
| | Gene Expression | 2 | 2019 | 1491 | 0.080 |
Why?
| | History, 20th Century | 2 | 2021 | 329 | 0.080 |
Why?
| | Structure-Activity Relationship | 2 | 2024 | 579 | 0.080 |
Why?
| | Organophosphates | 1 | 2010 | 156 | 0.070 |
Why?
| | Child | 5 | 2022 | 22308 | 0.070 |
Why?
| | Adolescent | 4 | 2022 | 22007 | 0.070 |
Why?
| | Spain | 3 | 2019 | 46 | 0.070 |
Why?
| | Protozoan Proteins | 1 | 2008 | 87 | 0.070 |
Why?
| | Peptides | 1 | 2013 | 978 | 0.070 |
Why?
| | Cell Survival | 1 | 2010 | 1129 | 0.070 |
Why?
| | Aurora Kinase B | 1 | 2025 | 10 | 0.060 |
Why?
| | Biomarkers, Tumor | 2 | 2024 | 1251 | 0.060 |
Why?
| | Chromosome Segregation | 1 | 2025 | 47 | 0.060 |
Why?
| | Bronchogenic Cyst | 1 | 2005 | 8 | 0.060 |
Why?
| | Cell Nucleus | 1 | 2008 | 609 | 0.060 |
Why?
| | Mouse Embryonic Stem Cells | 1 | 2025 | 31 | 0.060 |
Why?
| | Nectins | 1 | 2024 | 6 | 0.060 |
Why?
| | Cell Line | 1 | 2010 | 2885 | 0.060 |
Why?
| | Hepatitis C | 1 | 2007 | 250 | 0.050 |
Why?
| | Time Factors | 2 | 2017 | 6956 | 0.050 |
Why?
| | RNA Stability | 1 | 2025 | 116 | 0.050 |
Why?
| | CRISPR-Cas Systems | 1 | 2025 | 150 | 0.050 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2005 | 235 | 0.050 |
Why?
| | Mice, Inbred NOD | 1 | 2025 | 600 | 0.050 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2023 | 41 | 0.050 |
Why?
| | RNA Splicing | 1 | 2025 | 270 | 0.050 |
Why?
| | HIV-1 | 2 | 2010 | 895 | 0.050 |
Why?
| | Blood-Brain Barrier | 1 | 2024 | 144 | 0.050 |
Why?
| | Mice, Nude | 1 | 2024 | 691 | 0.050 |
Why?
| | Biological Transport | 1 | 2023 | 407 | 0.050 |
Why?
| | Longevity | 1 | 2023 | 175 | 0.050 |
Why?
| | Antiretroviral Therapy, Highly Active | 3 | 2010 | 285 | 0.050 |
Why?
| | Rats | 2 | 2024 | 5629 | 0.040 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2022 | 161 | 0.040 |
Why?
| | Recurrence | 1 | 2025 | 1110 | 0.040 |
Why?
| | Child, Preschool | 4 | 2017 | 11457 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 338 | 0.040 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2021 | 226 | 0.040 |
Why?
| | Iron | 1 | 2023 | 323 | 0.040 |
Why?
| | Trans-Activators | 1 | 2023 | 388 | 0.040 |
Why?
| | Forkhead Transcription Factors | 1 | 2022 | 199 | 0.040 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 91 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2021 | 5200 | 0.040 |
Why?
| | Th17 Cells | 1 | 2022 | 107 | 0.040 |
Why?
| | Intrinsically Disordered Proteins | 1 | 2021 | 37 | 0.040 |
Why?
| | Actin Cytoskeleton | 1 | 2021 | 103 | 0.040 |
Why?
| | Inflammasomes | 1 | 2022 | 134 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2021 | 316 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2023 | 419 | 0.040 |
Why?
| | Databases, Protein | 1 | 2020 | 87 | 0.040 |
Why?
| | Molecular Weight | 1 | 2020 | 329 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2021 | 215 | 0.040 |
Why?
| | Quantum Theory | 1 | 2020 | 92 | 0.040 |
Why?
| | Blood Viscosity | 1 | 2019 | 18 | 0.040 |
Why?
| | Proteasome Inhibitors | 1 | 2019 | 42 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2019 | 84 | 0.040 |
Why?
| | Mortality | 1 | 2021 | 358 | 0.040 |
Why?
| | Glucose | 1 | 2024 | 1041 | 0.040 |
Why?
| | Colitis | 1 | 2022 | 266 | 0.040 |
Why?
| | Antibiotic Prophylaxis | 1 | 2020 | 122 | 0.040 |
Why?
| | Repressor Proteins | 1 | 2022 | 425 | 0.040 |
Why?
| | Neuronal Plasticity | 1 | 2021 | 304 | 0.040 |
Why?
| | Disease Progression | 2 | 2021 | 2793 | 0.040 |
Why?
| | Immunotherapy | 1 | 2023 | 640 | 0.040 |
Why?
| | Rituximab | 1 | 2019 | 204 | 0.040 |
Why?
| | G1 Phase | 1 | 2018 | 72 | 0.040 |
Why?
| | CD4 Lymphocyte Count | 2 | 2010 | 284 | 0.040 |
Why?
| | Survival Analysis | 1 | 2021 | 1319 | 0.040 |
Why?
| | Ligands | 1 | 2020 | 667 | 0.040 |
Why?
| | Saccharomycetales | 1 | 2018 | 27 | 0.040 |
Why?
| | Anti-Bacterial Agents | 2 | 2020 | 1865 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2022 | 1150 | 0.030 |
Why?
| | Proteolysis | 1 | 2018 | 175 | 0.030 |
Why?
| | Piperidines | 1 | 2019 | 216 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2021 | 1398 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2021 | 900 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 2013 | 2158 | 0.030 |
Why?
| | Adenine | 1 | 2019 | 301 | 0.030 |
Why?
| | Viral Load | 2 | 2010 | 506 | 0.030 |
Why?
| | Computational Biology | 1 | 2021 | 661 | 0.030 |
Why?
| | Cell Division | 1 | 2018 | 798 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2021 | 1250 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2013 | 2929 | 0.030 |
Why?
| | Pyrimidines | 1 | 2019 | 477 | 0.030 |
Why?
| | Pyrazoles | 1 | 2019 | 443 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2018 | 501 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2025 | 2599 | 0.030 |
Why?
| | Cohort Studies | 2 | 2021 | 5799 | 0.030 |
Why?
| | Transcription Factors | 1 | 2023 | 1703 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2021 | 1431 | 0.030 |
Why?
| | Community-Acquired Infections | 1 | 2017 | 176 | 0.030 |
Why?
| | Protein Binding | 1 | 2021 | 2239 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2017 | 418 | 0.030 |
Why?
| | Retrospective Studies | 3 | 2019 | 16273 | 0.030 |
Why?
| | Databases, Factual | 1 | 2020 | 1444 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1970 | 0.030 |
Why?
| | Proteins | 1 | 2020 | 1010 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2022 | 2003 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 1040 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1261 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2018 | 712 | 0.030 |
Why?
| | Crystallography, X-Ray | 1 | 2015 | 485 | 0.030 |
Why?
| | Phenotype | 1 | 2021 | 3166 | 0.020 |
Why?
| | Recovery of Function | 1 | 2017 | 678 | 0.020 |
Why?
| | Administration, Oral | 1 | 2015 | 803 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2013 | 377 | 0.020 |
Why?
| | Neurons | 1 | 2021 | 1619 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2017 | 1983 | 0.020 |
Why?
| | Protein Multimerization | 1 | 2013 | 194 | 0.020 |
Why?
| | Brain | 1 | 2024 | 2858 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2892 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2022 | 5887 | 0.020 |
Why?
| | Pneumonia | 1 | 2017 | 656 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2015 | 2064 | 0.020 |
Why?
| | Furans | 1 | 2010 | 24 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2010 | 434 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 7739 | 0.020 |
Why?
| | Protein Sorting Signals | 1 | 2008 | 20 | 0.020 |
Why?
| | Deoxyribonucleases | 1 | 2008 | 24 | 0.020 |
Why?
| | Sequence Alignment | 1 | 2008 | 363 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2015 | 2504 | 0.020 |
Why?
| | Protein Transport | 1 | 2008 | 448 | 0.020 |
Why?
| | Pregnancy | 1 | 2019 | 7070 | 0.020 |
Why?
| | RNA, Viral | 1 | 2010 | 693 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2008 | 859 | 0.020 |
Why?
| | Hepacivirus | 1 | 2007 | 238 | 0.010 |
Why?
| | Risk Factors | 1 | 2019 | 10438 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2005 | 1052 | 0.010 |
Why?
| | Infant | 1 | 2007 | 9818 | 0.010 |
Why?
|
|
Moreno's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|